Laboratorios Rovi : Q2 2023 EBITDA above. Outlook nuanced slightly upwards
>Rovi is able to deliver some top-line growth despite the challenging situation - Total revenues increased +2% y-o-y in Q2 2023 reaching € 279m, a touch better than our estimates and the consensus and posting a 4pp sequential improvement which is remarkable given the weak momentum of Covid vaccine sales and the hard comps in heparines. This slight beat is due to a counter-intuitive surge in toll manufacturing sales to Moderna for its mRNA Covid vaccine related to tran...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.